Home LiteratureArticle Details
PMID: 3804900 Published · ppublish English Journal Article

The efficacy and safety of ciprofloxacin in the treatment of chronic Pseudomonas aeruginosa urinary tract infection.

The Journal of antimicrobial chemotherapy ·Vol. 18 Suppl D ·1986-11-00 ·Pages 123-7

Brown EM, Morris R, Stephenson TP

Abstract

The efficacy of ciprofloxacin in the treatment of chronic Pseudomonas aeruginosa urinary tract infection was assessed in 16 patients with functional or anatomical abnormalities of the urinary tract. Depending on renal function the dosage varied from 100 mg once daily to 250 mg twice daily. All patients were treated for 14 days. Bacteriological cure was documented for seven patients (44%) during the 8 week follow-up period. In a further seven patients the urine was sterile during treatment but relapse occurred within four weeks of completing the course. Persistence was noted in two cases, one of which was associated with the development of resistance. No significant adverse reactions were recorded. Chronic P. aeruginosa infection of the abnormal urinary tract can be very difficult to eradicate and ciprofloxacin may offer a valuable alternative to potentially more toxic parenteral agents.

MeSH Terms
Adult Aged Chronic Disease Ciprofloxacin/therapeutic use Female Humans Male Middle Aged Pseudomonas Infections/drug therapy Recurrence Urinary Tract Infections/drug therapy
Chemicals
Ciprofloxacin
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Brown E M
Morris R
Stephenson T P
Article Info
Journal
The Journal of antimicrobial chemotherapy
Abbr.
J Antimicrob Chemother
ISSN
0305-7453
Published
1986-11-00
Pages
123-7
Language
English
Region
England
NLM ID
7513617
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com